Search

Displaying results 2521 - 2530 of 9705 in total
  1. Drug

    Testosterone enanthate

    go.drugbank.com/drugs/DB13944
    ApprovedInvestigational

    Testosterone enanthate is an esterified variant of testosterone that comes as an injectable compound with a slow-release rate. … s Xyosted - a subcutaneous testosterone enanthate product for once-weekly, at-home self-administration with an easy-to-use, single dose, disposable autoinjector [L4659].

  2. Drug

    Ziftomenib

    go.drugbank.com/drugs/DB17171
    ApprovedInvestigational

    Ziftomenib is a potent and highly selective menin inhibitor. … [L54601] Ziftomenib works by preventing the protein-protein interaction between menin and KMT2A, a complex essential for maintaining the proliferation and survival of these leukemic cells.

  3. Drug

    Lunsotogene parvec

    go.drugbank.com/drugs/DB18278
    ApprovedInvestigational

    It is the first gene therapy to be approved under the Commissioner's National Priority Voucher (CNPV) pilot and represents one of the fastest BLA approvals in modern history, with a time between filing … [L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function

  4. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead. … potentially beneficial synergistic effects in treating chronic Hepatitis D, bulevirtide is also under investigation in clinical trial NCT03852433 (Phase 2b Study of Bulevirtide With [Peginterferon Alfa-2a

  5. Drug

    Nelistotug

    go.drugbank.com/drugs/DB19334
    Investigational

    Nelistotug is under investigation in clinical trial NCT06062420 (A Platform Study of Novel Immunotherapy Combinations as First-line Treatment in Participants With PD-L1 Positive Recurrent/metastatic Squamous

  6. Drug

    Ancitabine

    go.drugbank.com/drugs/DB20595
    Experimental

    Ancitabine has a monoisotopic molecular weight of 225.07 Da. … Ancitabine is a small molecule drug.

  7. Drug

    Galocitabine

    go.drugbank.com/drugs/DB21373
    Experimental

    Galocitabine has a monoisotopic molecular weight of 439.14 Da. … Galocitabine is a small molecule drug.

  8. Drug

    Alpibectir

    go.drugbank.com/drugs/DB21561
    Investigational

    Alpibectir has a monoisotopic molecular weight of 332.1 Da. … Alpibectir is a small molecule drug.

  9. Drug

    Ceperognastat

    go.drugbank.com/drugs/DB21591
    Investigational

    Ceperognastat has a monoisotopic molecular weight of 383.14 Da. … Ceperognastat is a small molecule drug.

  10. Drug

    Ranosidenib

    go.drugbank.com/drugs/DB21727
    Investigational

    Ranosidenib has a monoisotopic molecular weight of 453.12 Da. … Ranosidenib is a small molecule drug. Ranosidenib is under investigation in clinical trial NCT06387069 (A Study to Evaluate HMPL-306 in Patients With IDH1- and IDH2-mutated Acute Myeloid Leukemia).